Suven Life Sciences Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer s Dementia".
Press Release May 12 2026
Filed with NSE · · 3 pages · English
Release
Suven Life Sciences Limited on 6ix
Earlier from Suven Life Sciences
- Press Release Dec 11 2025
- Press Release Aug 13 2025
- Form MGT-7 FY 2024-25 (Annual Return)
- Annual Report FY 2024-2025
- Press Release Jul 16 2025
Later from Suven Life Sciences
- Press Release Jun 04 2026
- Suven Life Sciences: June 04, 2026Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Pha
- Suven Life Sciences Limited Press Release Jun 12 2026
- Suven Life Sciences Limited Press Release Jun 16 2026
- Suven Life Sciences Limited Press Release Jun 17 2026
Follow Suven Life Sciences into a list and get an email when it puts out news.
Follow Suven Life Sciences